"This predictive biomarker represents a paradigm shift in MSC...

"This predictive biomarker represents a paradigm shift in MSC therapeutics. "

I can't get my mind of this statement. The statement comes from people with no connection to MSB.

So the obvious question we holders would have.
Is it revelent to remestemcell?
Do we also have relevant data to support this so called paradigm shift in MSC therapeutics .
I believe we do, SI is confident. Why?

Let's go back to the presentation 16/July/21

https://investorsmedia.mesoblast.com/asx-announcements/

Just as important is the negative . Why did our cell therapy not work for those over 65?



Activation of the MSC is a critical attribute to the success of the treatment. Limited activation = limited success. Those factors marked above result in "Apoptosis " activation of MSC so they can do their job.

COVID ARDS, A inflammatory conditions.
Yes as highlighted in green below however those factors that activate the MSC would be found in the older population above 65 in far lower concentrations . They simply don't have significant numbers of T cells to provide apoptosis of the MSC. Highlighted red.



So in conclusion , though a randomized blinded trial although considered by many hear as a failed trial, we have the data .!

IBD data could also be very persuasive , direct injection to the site of inflammation. So far very dramatic efficacy. Compaird to the old trial ?

By the way the older population above 65 have also got reason to be hopeful . Problem could be solved by activation of MSC before infusion.

Good luck, time for me to enjoy the weekend.